Your prediction
Pros and Cons of Cumberland Pharmaceuticals in the next few years
Pros
?
M***** P*******
?
C******** o* t** e**********
?
S********** s********
Cons
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Cumberland Pharmaceuticals vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Cumberland Pharmaceuticals | - | - | - | - | - | - | - |
| Pacira Pharmaceuticals | 0.850% | 0.000% | 5.405% | 19.388% | 8.333% | -33.143% | -53.200% |
| Corcept Therapeutics Inc. | -1.800% | 15.059% | 21.989% | 53.499% | 39.222% | 235.211% | 423.077% |
| Supernus Pharmaceuticals | -1.060% | 10.500% | 5.742% | 45.395% | 2.791% | 52.414% | 95.575% |
News
Cumberland Pharmaceuticals Q2 Earnings Call Highlights
Key Points
- Interested in Cumberland Pharmaceuticals Inc.? Here are five stocks we like better.
- Cumberland completed the sale of its branded U.S. commercial portfolio to Apotex for $100 million
